Table 2:
Main patient baseline characteristics of the dialysis-dependent patients and independent patients.
| n = 25 | Hemodialysis dependent (n = 11) | Hemodialysis independent (n = 14) | P-value | |
|---|---|---|---|---|
| Age, years (mean, SD) | 70.7 (11.6) | 76.3 (6.6) | 65.9 (12.9) | .02 |
| >65 years (%, n) | 76.5 (19) | 90.9 (10) | 61.5 (9) | .166 |
| Gender, male (%, n) | 52 (13) | 36.4 (4) | 64.3 (9) | .238 |
| Previous CKD (GFR <60 mL/min) (%, n) | 44 (11) | 45.5 (5) | 42.9 (6) | 1 |
| De novo (%, n) | 76 (19) | 81.8 (9) | 71.4 (10) | .232 |
| FLC kappa/lambda (%, n) | 56 (14)/44 (11) | 54.6 (6)/45.5 (5) | 57.1 (8)/42.9 (6) | .165 |
| Baseline serum FLC, mg/L (median, IQR) | 9084 (4470–11 985) | 9940 (5862–14 302) | 8011 (3757–11 019) | .136 |
| Bortezomib-based chemotherapy (%, n) | 84 (21) | 90.9 (10) | 78.6 (11) | .604 |
| Time to MM target therapy initiation, days (median, IQR) | 5 (2.25–21.5) | 26 (2.5–41.75) | 4 (2.5–7) | .064 |
| Hematological response after first (at least PR) cycle (%, n) | 40 (10) | 45.5 (5) | 35.7 (5) | .697 |
| MM response (≥VGRP) (%, n) | 44 (11) | 36.4 (4) | 50 (7) | .689 |
| Involved FLC reduction by day 21 (%, n) | .138 | |||
| <50 | 15.8 (3) | 40 (2) | 7.1 (1) | |
| 50–75 | 21.1 (4) | 0 (0) | 28.6 (4) | |
| >75 | 63.2 (12) | 60 (3) | 64.3 (9) | |
| IHD (%, n) | 68 (17) | 36.4 (4) | 92.9 (13) | .007 |
| Number of IHD sessions | 15 | 12 | ||
| Serum creatinine, mg/dL (mean, SD) | 6.7 (2.8) | 7.5 (3.5) | 6 (2.95) | .215 |
| Proteinuria, mg/day (median, IQR) | 3400 (1350–6000) | 1775 (0.850–3075) | 5500 (3950–8200) | .002 |
| Kidney biopsy (%, n) | 44 (11) | 45.5 (5) | 42.9 (6) | 1 |
| Ca (mg/dL) (mean, SD) | 10.3 (2.18) | 9.2 (1.0) | 11.15 (2.5) | .027 |
| Ca >10.5 mg/dL (%, n) | 36 (9) | 18.2 (2) | 50 (7) | .208 |
| Diuresis >500 mL/day (%, n) | 62.5 (15) | 27.3 (3) | 85.7 (12) | .01 |
| Deaths (%, n) | 64 (16) | 81.8 (9) | 50 (7) | .208 |
CR: complete response; VGPR: very good partial response; PR: partial response; Ca: calcium.